Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
ELI LILLY & Co director Ralph Alvarez reported an equity award tied to his board compensation. He acquired 11.985 shares of common stock on February 17, 2026 at a reference price of $1,036.05 per share as a grant, bringing his directly held stake to 55,491.627 shares.
According to the disclosure, he elected to defer this compensation into stock units under the Lilly Directors' Deferral Plan, which will be settled in common shares after he leaves board service. The filing also reports 758 shares held indirectly by a trust, with Alvarez disclaiming beneficial ownership beyond his economic interest.
ELI LILLY & Co SVP Donald A. Zakrowski exercised restricted stock units and had shares withheld for taxes. On the transaction date, 184 restricted stock units were converted into 184 common shares at $0.00 per share. To satisfy tax obligations, 81.553 common shares were disposed of at $1040.00 per share, leaving 3,525.89 directly owned shares and 1,728.57 common shares held indirectly through a 401(k) plan. Each restricted stock unit represents a contingent right to receive one share of common stock.
Eli Lilly & Co EVP & CFO Montarce Lucas reported equity award activity involving company stock. Lucas exercised or converted 368 restricted stock units, receiving the same number of Eli Lilly common shares. To cover tax obligations, 159.733 common shares were disposed of in a tax-withholding transaction at $1040 per share, leaving 16,258.473 common shares owned directly after these transactions.
Eli Lilly & Co executive Kenneth L. Custer reported routine equity transactions. On February 16, he exercised 207 restricted stock units, receiving 207 shares of common stock at no cost. On the same date, 91.311 shares were disposed of at $1,040 per share to satisfy tax withholding obligations, leaving him with 10,140.544 directly owned shares.
Adrienne S. Brown, EVP and President of Lilly Immunology at Eli Lilly & Co, exercised restricted stock units into common shares and had shares withheld to cover taxes. On the transaction date, 391 restricted stock units were converted into 391 shares of common stock at a stated price of $0.0000 per share.
Following this derivative exercise/conversion, a tax-withholding disposition of 169.966 common shares was reported at $1040.0000 per share to satisfy tax obligations. After these transactions, Brown directly owned 5,142.342 shares of Eli Lilly common stock.
Eli Lilly executive insider filing shows a corrected share adjustment. On February 9, 2026, the reporting officer (EVP & CIDO) is shown as having acquired 4,599.164 shares of Eli Lilly common stock at $1,044.67 per share. After this adjustment, the executive directly owns 26,396.534 shares. The accompanying note explains this amended Form 4 corrects an earlier over-withholding of shares for tax obligations caused by an administrative error.
Eli Lilly and Company filed its annual report for the year ended December 31, 2025, outlining a global human pharmaceuticals business focused on cardiometabolic health, oncology, immunology, and neuroscience. Key growth drivers include diabetes, obesity, cardiovascular, cancer, immunology, and migraine/Alzheimer’s medicines such as Mounjaro/Zepbound, Trulicity, Jardiance, Verzenio, Omvoh, Taltz, Emgality, and Kisunla.
The company highlights extensive patent and data exclusivity across major products, with key expiries stretching into the 2030s and 2040s, and notes heavy reliance on intellectual property protection. It details a complex regulatory environment across the U.S., EU, Japan, China, and other markets, including the impact of biosimilars, generics, compounding and counterfeit incretin products, and evolving FDA, EMA, and other oversight.
Lilly discusses significant pricing and reimbursement pressures, including the U.S. Inflation Reduction Act, 340B dynamics, and an announced preliminary voluntary agreement with the U.S. government to lower certain prices and expand access, especially for obesity medicines. The report also describes large manufacturing capacity expansions globally, a 50,000-person workforce with 12,000 in R&D, and an experienced executive team. Shares of common stock outstanding were 943,357,420 as of February 9, 2026.
Eli Lilly & Co senior vice president, finance, and chief accounting officer Donald A. Zakrowski acquired additional company equity on February 9, 2026. He received 583.784 shares of common stock as a grant or award at $1,044.67 per share, bringing his directly held common stock to 3,423.443 shares.
He also received a grant of 199.472 restricted stock units, each representing a contingent right to one share of common stock, with both exercisable and expiration dates of February 16, 2029. In addition, 1,728.57 common shares are held indirectly through a 401(k) plan.
Eli Lilly executive Ilya Yuffa reported an acquisition of company stock through an equity award. On 02/09/2026, he received 4,162.504 shares of Eli Lilly common stock in a grant or other acquisition at a price of $1,044.67 per share. Following this award, he directly holds 32,304.111 shares of Eli Lilly common stock as EVP & President, LLY USA & Global Capabilities.
Eli Lilly executive Jacob Van Naarden, EVP and President of LLY Oncology & Head of Corporate Business Development, acquired 4,865.888 shares of Eli Lilly common stock on February 9, 2026 through a grant or award at $1,044.67 per share. Following this award, he directly holds 26,626.498 common shares. He also has indirect holdings of 4,342 shares through the Van Naarden Family Trust and 5,302 shares through a spousal lifetime access trust. The transactions are reported with a disclaimer that he only beneficially owns the securities to the extent of his pecuniary interest, and a footnote explains a February 5, 2026 transfer of 5,302 spouse-held shares into the spousal lifetime access trust, including 1,000 shares previously misreported as directly held.